Generic primidone
Executive Summary
Letter to the May 5 Journal of the American Medical Association from FDA's Stuart Nightingale, Peter Rheinstein and James Morrison says agency concludes "no bioequivalence problem with the generic product could be confirmed." The FDA letter responds to Sept. 4, 1987 article entitled "Increased Seizure Frequency with Generic Primidone," which detailed poor response of one patient who had been switched from Wyeth-Ayerst's Mysoline to the generic. An accompanying letter from Bolar points out that Cleveland Clinic incident "clearly indicated that there was no evidence of generic failure since this patient responded poorly" to both versions of the drug," and notes that Bolar sales of product were negatively impacted by article.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.